Disease status before and following HSCT with aNK-DLI
| Patient no. . | Diagnosis . | Prior chemotherapy regimens . | EPOCH-F cycles received . | Disease status . | Time to progression post-HSCT (d) . | Survival post-HSCT (mo) . | ||
|---|---|---|---|---|---|---|---|---|
| Enrollment . | Pre-HSCT . | Best response post-HSCT . | ||||||
| 1 | DSRCT | 3 | 1 | AD | SD | SD | 102 | 6.2 |
| 2 | EWS | 5 | 1 | AD | PD | SD | 55 | 5.6 |
| 3 | DSRCT | 3 | 3 | AD | PR | CR | No relapse | 8.5 |
| 4 | EWS | 4 | 3 | NED | CR | CR | No relapse | 27.4* |
| 5 | DSRCT | 2 | 2 | AD | SD | CR | 86 | 26.5* |
| 6 | RMS | 2 | 1 | NED | CR | CR | 79 | 10.4 |
| 7 | EWS | 3 | 3 | AD | CR | CR | 92 | 19.7* |
| 8 | EWS | 2 | 3 | AD | CR | CR | 187 | 10.2 |
| 9 | EWS | 2 | 3 | NED | CR | CR | No relapse | 12.5* |
| Patient no. . | Diagnosis . | Prior chemotherapy regimens . | EPOCH-F cycles received . | Disease status . | Time to progression post-HSCT (d) . | Survival post-HSCT (mo) . | ||
|---|---|---|---|---|---|---|---|---|
| Enrollment . | Pre-HSCT . | Best response post-HSCT . | ||||||
| 1 | DSRCT | 3 | 1 | AD | SD | SD | 102 | 6.2 |
| 2 | EWS | 5 | 1 | AD | PD | SD | 55 | 5.6 |
| 3 | DSRCT | 3 | 3 | AD | PR | CR | No relapse | 8.5 |
| 4 | EWS | 4 | 3 | NED | CR | CR | No relapse | 27.4* |
| 5 | DSRCT | 2 | 2 | AD | SD | CR | 86 | 26.5* |
| 6 | RMS | 2 | 1 | NED | CR | CR | 79 | 10.4 |
| 7 | EWS | 3 | 3 | AD | CR | CR | 92 | 19.7* |
| 8 | EWS | 2 | 3 | AD | CR | CR | 187 | 10.2 |
| 9 | EWS | 2 | 3 | NED | CR | CR | No relapse | 12.5* |
Gray rows highlight patients who developed aGVHD.
Still alive.
AD, active disease; CR, complete remission with no evidence of disease; DSRCT, desmoplastic small round cell tumor; EWS, Ewing sarcoma; RMS: Rhabdomyosarcoma. NED, no evidence of disease; PD, progressive disease; PR, partial remission with residual active disease; SD, stable active disease.